MC1286: Phase I/II Bortezomib, melphalan and low dose TBI conditioning for patients undergoing autologous stem cell transplantation for multiple myeloma

Location:

Rochester, Minn.

Trial status:

Open for Enrollment

NCT ID:

NCT01936090

IRB Number:

12-008546